iShares MSCI Singapore ETF vs Guardant Health Inc. Common Stock — how do they compare? iShares MSCI Singapore ETF trades at $31.6 (market cap $1.53B), while Guardant Health Inc. Common Stock trades at $165.58 (market cap $22.58B). The key difference: Guardant Health Inc. Common Stock is far larger — about 14.8× iShares MSCI Singapore ETF's market cap, and Guardant Health Inc. Common Stock is trading nearer its 52-week high, iShares MSCI Singapore ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Singapore ETF for 45 Days and Guardant Health Inc. Common Stock for 0 Days on average.
| EWS | GH | |
|---|---|---|
Market Cap | $1.53B | $22.58B |
Volume | 1,666,115 | 2,200,599 |
Sector | Broad Market / Factor | Health |
52-Week High | $34.57 | $187.22 |
52-Week Low | $26.71 | $61.73 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | — | $23.22B |
Signals from Pluang's Aura AI — not financial advice
EWS, the iShares MSCI Singapore ETF, trades at $32.48, down 2.17% amid bearish technical signals. The ETF recently hit a 52-week high, driven by Singapore's economic strength and AI momentum, but faces selling pressure with key support at $32. Financial ratios are unavailable, limiting fundamental clarity.
Outlook remains mixed; Singapore's growth and institutional interest offer upside, but stretched valuations and technical weakness pose risks. Investors should weigh regional economic resilience against potential pullbacks in a volatile market.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →Guardant Health develops blood tests for cancer care. Its tests support genomic profiling, cancer screening, recurrence monitoring, and treatment decisions.
Read more on GH →